Navigation Links
SARcode Bioscience Completes $44 Million Series B Financing
Date:7/18/2011

BRISBANE, Calif., July 18, 2011 /PRNewswire/ -- SARcode Bioscience, Inc., a privately-held biopharmaceutical company, announced today the completion of a $44 million Series B private equity financing.  The financing round was led by Sofinnova Ventures and was augmented by the additional backing of Rho Ventures and existing investors Alta Partners and Clarus Venture Partners.

(Logo: http://photos.prnewswire.com/prnh/20110718/FL36481LOGO)

"We believe that SARcode is uniquely positioned to make significant breakthroughs in the treatment of dry eye that could improve therapeutic options for millions of patients," commented Garheng Kong, General Partner of Sofinnova Ventures.  "SARcode's proprietary compound has demonstrated the ability to alleviate both the signs and symptoms of dry eye by directly targeting the inflammatory origin of this debilitating disease," Kong added.  "We have been impressed by the broad ophthalmic product development and marketing experience of the SARcode executive team and look forward to working with them and the investor syndicate as the company's lead dry eye program moves into Phase 3 clinical trials," said Martin Vogelbaum, Partner at Rho Ventures.

Proceeds from the Series B financing will largely support further clinical development of SAR 1118, SARcode's lead compound for the treatment of dry eye syndrome.  SAR 1118 is a first-in-class, topical small-molecule integrin antagonist that inhibits T-cell mediated inflammation, a key component of dry eye.  In a Phase 2 randomized, placebo-controlled trial of 230 subjects with dry eye disease, SAR 1118 demonstrated an improvement in corneal staining at 12 weeks and an increase in tear production as early as 2 weeks.  In addition, subjects receiving SAR 1118 reported dose-dependent improvements in visual-related function at 12 weeks, which included the ability to read, drive at night, use a computer and watch television.  SAR 1118 was
'/>"/>

SOURCE SARcode Bioscience, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
2. SARcode Corporation Announces Phase 2 Study Results of SAR 1118 Topical Ophthalmic Solution for the Treatment of Dry Eye
3. Quinton Oswald Named Chief Executive Officer of SARcode Corporation
4. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
5. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
6. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
7. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
10. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
11. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 /PRNewswire/ ... market research report is available in ... for Hospital-Acquired Infection Control (Sterilization, Disinfection, ... http://www.reportlinker.com/p01618925/The-Market-for-Hospital-Acquired-Infection-Control-Sterilization-Disinfection-Testing-and-Treatment.html Given ... infections (HAIs), demand has increased for ...
(Date:8/20/2014)... YORK , Aug. 20, 2014 /PRNewswire/ ... research report is available in its catalogue: ... in Canada, Key Trends and Opportunities to ... Synopsis The report provides ... into the Canadian personal accident and health ...
(Date:8/20/2014)... Aug. 20, 2014 Research and ... "Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services ... report to their offering. ... applications and geography) - Size, Share, Global Trends, ... Segmentation and Forecast, 2013 - 2020", suggests that ...
Breaking Medicine Technology:The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 2The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 3The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 4The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 5The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 6Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 2Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 3Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 4Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 5Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 6Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 7Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 8Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 9Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 10Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 11Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 12Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 13Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 14Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 15Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 16Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 17Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 18Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 19Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 20Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 21Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 22Personal Accident and Health Insurance in Canada, Key Trends and Opportunities to 2017 23Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and Geography) - Research Report, 2013 - 2020 2
... July 6 Biodel Inc. (Nasdaq: BIOD ) announced today that the following ... presented during the 37th Annual Meeting and Exposition of the Controlled Release Society in ... , Oral Presentation : ... #51, Oral session on peptides and proteins, Monday July ...
... , July 6 Sangamo BioSciences, Inc. ... demonstrating the preclinical efficacy of a human stem cell ... proprietary zinc finger DNA-binding protein nuclease (ZFN) technology. The ... gene, which encodes an important receptor for HIV infection, ...
Cached Medicine Technology:Biodel Announces Schedule for Presentations at the 37th Annual Meeting and Exposition of the Controlled Release Society 2Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells 2Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells 3Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells 4Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells 5Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells 6
(Date:8/20/2014)... in Australia examined patient and tumor characteristics for ... tumor cell growth) in an effort to increase ... , Author: Sarah Shen, M.B.B.S., ... colleagues. , Background: The tumor characteristic known ... been connected with prognosis and survival in melanoma ...
(Date:8/20/2014)... researchers have discovered that the immune system is defective ... major reason why sufferers have ongoing issues with pain. , ... world could also help to explain why some painkillers ... syndrome (IBS) affects up to 10% of the community. ... involve unexplained gut pain, which often has the greatest impact ...
(Date:8/20/2014)... vaccines is now, Free content, The time to ... commentary being published early online today in ... Yale School of Public Health write that the relentless ... outbreak represent a public health crisis that shows no ... have been developed in the last decade, yet the ...
(Date:8/20/2014)... -- Pigs, hearts transplanted into baboons survived for more ... previously achieved, researchers report. The work is part ... to shorten transplant waiting lists. In this study, ... abdomens. The genetic engineering and new methods of suppressing ... hearts to survive for more than a year. ...
(Date:8/20/2014)... (HealthDay News) -- Loss of brain cells that act ... seniors have trouble falling and staying asleep, a new ... be especially severe and often results in nighttime confusion ... analyzed data from the Rush Memory and Aging Project, ... 65 and are being followed until death, at which ...
Breaking Medicine News(10 mins):Health News:Patient, tumor characteristics for high-mitotic rate melanoma 2Health News:Pain treatments less effective for those with irritable bowel 2Health News:News from Annals of Internal Medicine 2Health News:Pigs' Hearts Beat for a Year in Baboons' Abdomens 2Health News:Seniors' Sleep Woes May Be Linked to Loss of Brain Cells 2
... Goodwin HealthDay Reporter , WEDNESDAY, March 14 ... with acute myeloid leukemia, researchers were able to more ... going into remission, and which ones would respond well ... Doctors from Memorial Sloan-Kettering Cancer Center in New York ...
... HealthDay Reporter , WEDNESDAY, March 14 (HealthDay News) -- People ... a genetic predisposition to be overweight, compared to those who ... The findings don,t prove that the exercise is the ... something else could explain why those who walked were thinner, ...
... of UCLA suggested that meditating for years thickens the ... between brain cells. Now a further report by UCLA ... Luders, an assistant professor at the UCLA Laboratory of ... have larger amounts of gyrification ("folding" of the cortex, ...
... acts of racial discrimination is enough to depress anyone, ... to stress with stoicism and emotional control experience more ... of North Carolina at Chapel Hill. The study, ... Moderators of the Racial DiscriminationDepressive Symptoms Association Among African-American ...
... molecules in a drop of a patient,s blood to detect ... drug ferry that doesn,t release its toxic contents until it ... be game changers in how we diagnose, monitor and treat ... the California Institute of Technology, and a member of the ...
... infected with hepatitis C virus (HCV) would likely ... published in Clinical Infectious Diseases and ... mortality and morbidity, however, will require a coordinated ... also linking those infected with the treatment they ...
Cached Medicine News:Health News:Detailed Gene Scan Might Help Guide Leukemia Treatment 2Health News:Detailed Gene Scan Might Help Guide Leukemia Treatment 3Health News:Detailed Gene Scan Might Help Guide Leukemia Treatment 4Health News:Brisk Daily Walk Could Counter 'Obesity Genes' 2Health News:Evidence builds that meditation strengthens the brain, UCLA researchers say 2Health News:Hiding emotions may exacerbate depression among black men who confront racial discrimination 2Health News:Fighting cancer with nanotechnology 2Health News:Broader screening for hepatitis C would be cost effective, study suggests 2
... pumps deliver critical performance for all vacuum ... optimizes pump performance to suit all applications. ... convenient checking of proper oil levels at ... is designed to work with all Thermo ...
Produces vacuum pressures required for 96 well kits...
Variable Speed Pump...
Inquire...
Medicine Products: